Clinical Trial: Masitinib in Combination With Standard of Care in the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)

U.S., Sept. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07174492) titled 'Masitinib in Combination With Standard of Care in the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)' on Sept. 11.

Brief Summary: The objective is to compare the efficacy and safety of masitinib in combination with riluzole versus matched placebo in combination with riluzole for the treatment of Amyotrophic Lateral Sclerosis (ALS).

Study Start Date: Jan. 01, 2026

Study Type: INTERVENTIONAL

Condition: Amyotrophic Lateral Sclerosis (ALS)

Intervention: DRUG: Masitinib 4.5 mg/kg/day

masitinib + riluzole

DRUG: Placebo

Placebo + riluzole

Recruitment Status: NOT_YET_RECRUITING

Sponsor: AB Science

Disc...